Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
5
Blackpink's solo journeys: Complementary paths, not competition
-
6
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
7
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
8
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
9
Actor Song Joong-ki welcomes second child in Rome
-
10
Main opposition pushes to ease, not postpone, tax on crypto gains
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
SK Bioscience to invest W150b to beef up vaccine production capacity
By YonhapPublished : June 21, 2021 - 14:53
SK Bioscience Co., a major South Korean pharmaceutical firm, said Monday it plans to invest 150 billion won ($132 million) through 2024 to expand its production capacity of COVID-19 vaccines.
SK Bioscience said the investment is meant to increase the production capacity of the production line based in Andong, about 270 kilometers south of Seoul.
The investment will also be spent on building facilities to develop vaccines utilizing the so-called messenger RNA (mRNA) technology, which recently came under the spotlight amid the COVID-19 pandemic.
Among major COVID-19 vaccines currently available in the market, those from Pfizer and Moderna use the technology.
The pharmaceutical firm said the move comes in line with the growing demand for COVID-19 vaccines.
Currently, SK Bioscience produces British-Swedish pharmaceutical giant AstraZeneca's COVID-19 vaccine in South Korea under a partnership deal.
Last year, the affiliate under SK Group also signed a deal with the US vaccine producer Novavax for consignment production of the Novavax COVID-19 vaccine.
In May, the company's production line also won a Good Manufacturing Practice certification from the European Medicines Agency. (Yonhap)
SK Bioscience said the investment is meant to increase the production capacity of the production line based in Andong, about 270 kilometers south of Seoul.
The investment will also be spent on building facilities to develop vaccines utilizing the so-called messenger RNA (mRNA) technology, which recently came under the spotlight amid the COVID-19 pandemic.
Among major COVID-19 vaccines currently available in the market, those from Pfizer and Moderna use the technology.
The pharmaceutical firm said the move comes in line with the growing demand for COVID-19 vaccines.
Currently, SK Bioscience produces British-Swedish pharmaceutical giant AstraZeneca's COVID-19 vaccine in South Korea under a partnership deal.
Last year, the affiliate under SK Group also signed a deal with the US vaccine producer Novavax for consignment production of the Novavax COVID-19 vaccine.
In May, the company's production line also won a Good Manufacturing Practice certification from the European Medicines Agency. (Yonhap)
![[Today’s K-pop] Babymonster logs 100m views with ‘Drip’ music video](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/11/22/20241122050051_0.jpg&u=20241122172213)